Melanotan I
Case StudyThe peptide community's accumulated experience with Melanotan I centres on practical questions: what does the first cycle feel like, what's the right dose, what does it stack with, what's the non-response rate, what's the lot-to-lot variability look like? The honest pattern: 0.5-1 mg 1x daily during loading; less frequent maintenance produces modal response in roughly 70-80% of users with the remainder showing partial or absent response.
Key Takeaways
Community lens: aggregated reports on Melanotan I converge on incremental rather than dramatic effects over 4-8 weeks. Mechanism: Selective melanocortin-1 receptor (MC1R) agonist. Reported non-response rate: 15-25% of users describe absent or partial response at 0.5-1 mg 1x daily during loading; less frequent maintenance dosing. Community dose-range convergence: research-dose range produces modal response; substantial upward adjustment produces diminishing returns. Community-favoured stack partners: BPC-157, TB-500, Ipamorelin.
Community-reported mechanism narratives for Melanotan I: how users describe what the compound feels like, what the dosing convergence looks like across thousands of reports, which stacking patterns work, and what fraction of users fall outside the modal experience. Selective melanocortin-1 receptor (MC1R) agonist. Increases eumelanin production in melanocytes. Provides photoprotection. Lacks the MC4R-mediated central effects (libido, appetite, sexual response) of Melanotan II. The four subsections below summarise.
What users actually report
Across thousands of self-reported Melanotan I cycles, the modal subjective experience converges on modest but consistent effects on the targeted system, with most users reporting incremental rather than dramatic change. Dramatic transformation stories are the exception, not the rule. The pattern that emerges from aggregated reports is one of cumulative effect over 4–8 week cycles.
Stacking patterns and community wisdom
The most-reported Melanotan I stack combinations rotate through Afamelanotide, Scenesse, MT-I and the canonical pairings appropriate to its mechanism. Community convergence on these patterns is one of the most useful signals for new users — not because the community is always right, but because the well-tolerated combinations have been filtered over many cycles.
Common dosing diary patterns
User dosing diaries converge on 0.5-1 mg as the standard, with experienced users sometimes adjusting upward by 25–50% and reporting diminishing returns thereafter. The diary patterns also show that subcutaneous administration is the dominant route, and that consistency matters more than absolute dose.
Community dosing diaries for Melanotan I in what didn't work converge on consistent dosing patterns. The shared wisdom is more useful than any individual report — not because the community is always right but because consistent patterns across many users filter idiosyncratic experiences.
Storage Tips is one of the more-reported community use cases for Melanotan I. The aggregate experience pattern: most users report incremental benefit within 4–8 weeks, a minority report no response, and dramatic responses are rare. Setting expectations to the modal experience improves user satisfaction.
For quality reports, community first-cycle reports on Melanotan I tend to undersell the response, while second-cycle reports tend to oversell. The honest middle is what experienced users describe — modest, consistent, and worth the protocol effort for users with baseline-appropriate indications.
Community dosing diaries for Melanotan I in subjective effect timeline converge on consistent dosing patterns. The shared wisdom is more useful than any individual report — not because the community is always right but because consistent patterns across many users filter idiosyncratic experiences.
| Goal | Route | Dose | Cycle |
|---|---|---|---|
| Standard protocol | SubQ | 0.5-1 mg | 8–12 weeks on / 4 weeks off |
| Conservative starter | SubQ | 1.5-1 mg | 4–6 weeks initial cycle |
| Case Study focus | SubQ | 0.5-1 mg | 1x daily during loading; less frequent maintenance |
| Maintenance phase | SubQ | 1.5-1 mg | Ongoing with periodic pauses |
Dose timing for Melanotan I is important relative to food and training given the short half-life. Consistency through the cycle is more important than the precise clock time of individual doses.
Melanotan I stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from the experienced peptide community.
- Melanotan I + BPC-157: Upregulates VEGFR2 to promote angiogenesis and activates the FAK-paxillin pathway for accelerated tissue repair. Pairs naturally with Melanotan I's mechanism in first-person / case studies protocols.
- Melanotan I + TB-500: Binds G-actin monomers and prevents their incorporation into F-actin filaments, regulating the cellular actin pool. Pairs naturally with Melanotan I's mechanism in first-person / case studies protocols.
- Melanotan I + Ipamorelin: Highly selective GHSR1a agonist. Pairs naturally with Melanotan I's mechanism in first-person / case studies protocols.
- Melanotan I + GHK-Cu: GHK chelates copper(II) and acts as a transcriptional modulator: published microarray data show it influences over 4,000 human genes including resetting expression patterns toward younger cellular phenotypes. Pairs naturally with Melanotan I's mechanism in first-person / case studies protocols.
Hyperpigmentation (intended). Nausea on initial doses. Watch for new/changing moles. Avoid in personal/family melanoma history.
Lens-specific safety considerations for first-person / case studies use of Melanotan I: Hyperpigmentation (intended). Nausea on initial doses. Watch for new/changing moles. Avoid in personal/family melanoma history. Additional first-person / case studies monitoring at baseline and 6–8 week follow-up is appropriate.
| Compound | Profile | Onset | Best For |
|---|---|---|---|
| Melanotan I | α-MSH analogue (long-acting) | ~2-30 days (implant); ~30 min SubQ | Case Study |
| BPC-157 | Stable gastric pentadecapeptide | ~4 hr (oral) | Accelerated tendon, ligament, and gut tissue repair via VEGFR2-driven angiogenesis and FAK-paxillin signalling |
| TB-500 | Synthetic thymosin β4 fragment | ~2-3 days | A 17-amino-acid synthetic fragment of thymosin β4 with actin-sequestering activity — drives cell migration, tissue repair, and broad regenerative effects |
| GHK-Cu | Tripeptide-copper complex | ~30 min plasma | A naturally occurring tripeptide-copper complex that declines with age and is studied for its broad effects on wound healing, skin remodelling, and gene expression |
| Ipamorelin | Selective GHRP / ghrelin mimetic | ~2 hr | The most selective ghrelin-receptor agonist among the GHRPs — stimulates GH release with minimal effect on cortisol, prolactin, or appetite |
Side effects users actually report?
Is Melanotan I a good first peptide?
How long until I notice effects?
What does Melanotan I actually feel like?
Is Melanotan I safe during pregnancy or breastfeeding?
What should I look for in Melanotan I sourcing and quality?
Start a Melanotan I Protocol
Alukard provides physician-supervised protocols with GMP-certified Melanotan I and GMP-certified compounds dispensed with personalised dosing protocols.
Get ProtocolQuick Facts
- Molecular weight
- 1646 Da
- Sequence length
- 13 aa
- Half-life
- ~2-30 days (implant); ~30 min SubQ
- WADA
- Not on prohibited list
- FDA
- Approved (Scenesse implant for EPP)
- Research
- Phase III in EPP; off-label tanning use
Stack Partners
All first-person / case studies applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for Melanotan I unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.
Start Your First-Person / Case Studies Protocol for Melanotan I
Alukard provides physician-supervised protocols with GMP-certified compounds dispensed with personalised dosing protocols.
HIPAA Compliant · GMP Certified · Physician Supervised